BioSpace News Archive

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NeoImmuneTech’s NT-I7, the only clinical-stage long-acting human IL-7, for the treatment of Progressive Multifocal Leukoencephalopathy.

Additional 40mg/kg adult cohort demonstrates incremental efficacy; data reinforces AT-007 favorable safety and efficacy profile

Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001)

BeyondSpring, a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced positive topline results at the pre-specified interim analysis of its PROTECTIVE-2 Phase 3 trial, evaluating Plinabulin in combination with Neulasta versus Neulasta alone.

ATUM and Phylex BioSciences have entered into a collaboration to leverage ATUM’s Leap-In Transposase® platform to develop the cell line essential to the manufacturing of Phylex’s universal SARS coronavirus vaccine candidate.

Preclinical data for Sanofi’s investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research Virtual Annual Meeting II on June 22-24.

FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high or low without scanning

MedX Health Corp. announces that it has signed an Exclusive Distribution Agreement with EMC LABS, S.A.P.I. DE C.V., operating as MedX Mexico, which plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform.